Nadix

Quick links to important sections

Nadix

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nadix

Property Description
Active ingredient Nadifloxacin
Form Cream, Gel, Lotion
Pharmacological class Fluoroquinolone Antibiotic
Common use Topical antibacterial agent
Origin Synthetic

Nadix is a specialized brand name for a medication formulated for topical use on the skin, distinguished as a dermatological preparation. Its efficacy relies on the active ingredient, nadifloxacin, which is a synthetic antimicrobial substance designed to combat pathogenic bacteria.

What Type of Medicine is Nadix? (Identity and Class)

The active substance, nadifloxacin, belongs to the synthetic pharmacological group of fluoroquinolone antibiotics, which are used as antibacterial agents. Nadifloxacin is designated under the code D10AF05, highlighting its targeted use in treating microbial skin conditions. The substance is structurally a pyridoquinoline derivative and possesses a broad spectrum of activity against both Gram-positive and Gram-negative bacteria commonly associated with skin infections.

Nadifloxacin: Composition and Form (Substance and Preparation)

Nadix is formulated as a single-agent product, containing only nadifloxacin as the primary medicinal component. It is typically supplied in preparations such as a cream or a gel, which are necessary to facilitate the topical route of administration. This formulation allows the substance to penetrate the layers of the skin, a feature that facilitates exposure to bacteria colonizing hair follicles and deeper skin structures. This localized approach is used for conditions such as infected hair follicles (folliculitis).

What is the General Purpose of This Topical Antibacterial? (High-Level Benefit)

The fundamental therapeutic purpose of this product is to control and resolve infections that originate from bacteria localized on the skin. This benefit is achieved through the drug's bactericidal action, meaning it kills susceptible bacteria by interfering with their ability to replicate their DNA. This antimicrobial effect supports the reduction of the bacterial population and aids the skin in clearing the infectious process.

What side effects are possible with Nadix?

Possible Side Effects and Safety Information

The safety profile of Nadix (Nadifloxacin) is primarily defined by local reactions due to its topical administration, with systemic adverse effects being uncommon. The frequency and types of possible side effects are classified based on official regulatory documents, such as those from the FDA and European health authorities.


Adverse Reactions by Frequency

Adverse reactions associated with this medicine are mainly limited to the Skin and Subcutaneous Tissue Disorders system-organ class. The most frequently documented reactions are typically confined to the site of application.

Classification Documented Reactions
Common Pruritus (itching), burning sensation, erythema (redness), flushing, papules, contact dermatitis, dry skin, and a hot feeling at the application site.
Rare Skin hypopigmentation (lightening of the skin color).

Serious adverse reactions are rare, but the product is formally contraindicated in individuals with known hypersensitivity or allergy to nadifloxacin or any excipients in the formulation, as indicated in prescribing information.


Population-Specific Safety Considerations and Restrictions

Official labeling includes specific constraints regarding use in certain populations and under particular conditions:

  • Pregnancy and Lactation: Use during pregnancy is advised only after a careful assessment of maternal benefit versus potential risks, due to a lack of controlled human data. The medicine should not be used during lactation (breastfeeding) and must not be applied to the breast area, as it is excreted in human milk.
  • Pediatric Use: Safety and efficacy have not been established in children younger than 14 years.
  • Safety Restrictions: The product is strictly for dermal use and must not contact the eyes or other mucous membranes. Patients should avoid artificial UV radiation (e.g., sunbeds) and minimize strong sun exposure, as concurrent use with other topical irritants may increase the risk of skin irritation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nadix (Nadifloxacin) addresses overdose risks through two distinct types of exposure: excessive application to the skin and accidental oral ingestion. The information presented here strictly reflects statements from official government regulatory documents.

Documented Overdose Manifestations

Exposure Type Documented Manifestation
Excessive Topical Use Marked reddishness of the skin and localized discomfort resulting from repeated and excessive application.
Oral Ingestion Systemic effects are not documented, but the event itself is classified as an emergency.

Emergency Actions and Required Help-Seeking

Urgent medical assistance is required only following the specific event of involuntary oral ingestion of the product. Official labeling mandates that the user seek immediate medical attention in this specific scenario.

For the purpose of managing non-minor oral ingestion, regulatory information states that a suitable method of gastric emptying, such as gastric lavage, should be considered by a healthcare professional. Management is entirely symptomatic and supportive, as no specific antidote is documented or known for Nadifloxacin overdose. Excessive application to the skin primarily results in a localized dermal reaction (redness and discomfort). No population-specific overdose considerations are formally documented in the official regulatory sections.

Therapeutic Uses of Nadix

What Nadix Treats: Main Uses and Benefits

Nadix (Nadifloxacin) is a topical antibacterial agent commonly used for managing conditions characterized by periods of heightened symptoms driven by bacterial proliferation on the skin. Its use is relevant in cases where additional symptomatic support is needed for acne and bacterial skin infections.

The medication is commonly used to help with symptoms related to inflammatory or irritative states associated with mild to moderate acne vulgaris, as well as managing localized acute or disruptive episodes of bacterial skin infection, including folliculitis and impetigo. It is also considered relevant when supportive symptom management is appropriate for pre-existing dermatoses, such as infected eczema or minor wounds, that develop a secondary bacterial infection.

“The primary purpose is to address the symptoms of localized inflammation and tenderness that arise from bacterial proliferation.”

This action supports the process of infection clearance, which may assist in easing the associated signs of distress and helping to maintain a sense of stability when symptoms are more noticeable. The therapeutic benefit supports symptom management, helping ease physical discomfort and supporting day-to-day comfort.

Quick Fact: Relief for Inflammatory Symptoms
Common Focus: Relevant in conditions presenting with pus-filled pustules, tender papules, and localized redness.
Symptom Focus: Used to help address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

Regulatory References

  1. Philippine Food and Drug Administration (FDA) Verification Portal

Eligibility and Restrictions for Use

The eligibility for using Nadix (Nadifloxacin) is strictly defined by regulatory guidelines based on patient characteristics and clinical status.

Eligibility Scope

Classification Population Status Rule as Per Regulatory Label
Contraindicated Hypersensitivity Must not be used by patients with a known allergy to Nadifloxacin or any other ingredient in the formulation.
Not Recommended Age-Related Safety and effectiveness have not been established in children under 14 years of age.
Prohibited Lactation Should not be used during the nursing period, and must not be applied to the breast area.
Conditional Use Pregnancy Use is permitted only after careful benefit-risk evaluation by a healthcare professional, due to lack of controlled human trial data.
Restricted Use Skin Integrity & UV Must not be applied to broken or severely damaged skin, and patients should avoid artificial UV radiation and solar light exposure due to potential photosensitivity risk.

Resulting Eligibility Structure

Use of Nadix is generally established for adults and adolescents 14 years and older when none of the specified contraindications or restrictions apply. The official profile prohibits use in cases of known allergy or during breastfeeding, and places firm constraints on pediatric use and application site conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nadix (Nadifloxacin) is significantly structured by its topical route of administration and resulting minimal systemic absorption. Regulatory sources state that the systemic concentration of the active ingredient is very low, making clinically significant interactions with medicines administered by the systemic route very unlikely.


The primary documented interactions are local, classified as Administration-Timing Interactions. Co-administration with other topical preparations should be avoided due to the potential for physical or chemical interference at the application site.

Specifically, use alongside peeling agents, astringents, or products containing irritant substances (such as alcohols or aromatic agents) may result in an increase in local skin irritation.


The regulatory constraint is to avoid simultaneous application with other dermatological products. Official labeling suggests that Nadifloxacin should only be used in monotherapy or with separation from other local treatments when specific co-administration data are not available. This low systemic interaction risk is the core regulatory basis for the medicine’s interaction profile.

Mechanism of Action

The mechanism of Nadix (Nadifloxacin) is defined by two primary biological actions exerted locally within the skin tissue: an antimicrobial action against the pathogen and a modulation of the host's inflammatory response.


Dual-Enzyme Inhibition for Microbial Control

This domain covers the drug's core molecular mechanism, where it acts as a selective inhibitor of two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. By binding to and stabilizing the cleaved DNA-enzyme complex, this action disrupts the bacterial cell's ability to replicate and maintain its genetic integrity. The cascade results in significant DNA damage, leading directly to the bactericidal effect (bacterial cell death) .


Modulation of Local Inflammatory Pathways

This secondary domain describes the drug's interaction with the host's immune system, specifically the modulation of activity within human cells like Keratinocytes and Peripheral Blood Mononuclear Cells (PBMC). Nadifloxacin suppresses the downstream release of key pro-inflammatory cytokines (chemical messengers) such as IL-6 and IL-8, which are chemical messengers central to localized inflammatory signaling. This modulation restricts the physiological signaling of pro-inflammatory mediators, altering the resulting inflammatory cascade within the affected tissue.

Dosage and Administration Information

Administration Guidelines for Nadix (Nadifloxacin)

Nadix is a topical fluoroquinolone product, most commonly formulated as a 1% cream or gel. The instructions for its use define the application method and duration.

Administration Scope Detail
Route of Administration Strictly Topical (Dermal); the product is for external use only and must not be applied to the eyes or other mucous membranes.
Dosing Schedule Apply an adequate amount or a thin layer of the cream or gel to cover the affected skin lesions. The dose is determined by the required coverage, not a fixed measure.
Preparation Requirements Before each application, the affected skin area must be carefully cleaned and dried thoroughly.
Age-Group Rules Use is not recommended for children younger than 14 years as the safety and efficacy have not been fully established in this age group.
Missed-Dose Rules If an application is missed, the patient should skip that application and apply the next dose at the scheduled time; do not use a double quantity to compensate.

Procedural Structure and Constraints

The standard frequency for Nadifloxacin application is Twice Daily (BID), typically once in the morning and once before bedtime, throughout the defined treatment course. The duration of treatment is generally up to 8 weeks but may be extended to a maximum of 12 weeks for conditions like acne vulgaris. Standard practice specifies that the product must not be used under occlusive dressings (e.g., airtight bandages).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nadix

Evidence for Use in Mild to Moderate Acne Vulgaris

Research exploring Nadix for acne focuses primarily on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time. These studies enrolled participants, mainly adolescents and young adults diagnosed with mild to moderate facial acne. Researchers primarily measured changes in the total number of acne lesions and standardized measures like the Investigator Global Assessment (IGA) score. Studies conducted during periods of increased symptom activity reported that the observed populations showed patterns of change in lesion counts over the defined time intervals, typically lasting 8 to 12 weeks. The research also examined comparisons against a non-active gel or cream (a placebo) and against other established topical treatments.

Evidence for Use in Superficial Bacterial Skin Infections

Nadix was studied for its use in specific, localized bacterial skin infections, such as folliculitis and impetigo. The research consisted mainly of comparative clinical trials, many of which were open-label, involving both adults and children. Studies typically observed responses over defined time intervals, with follow-up durations lasting up to eight weeks. Researchers focused on outcomes describing episodic or acute changes, monitoring endpoints related to physical discomfort and overall clinical success (clearance or significant improvement of infection signs). The evidence base for these infections is characterized by studies that are generally smaller in scale and often lacked a placebo comparator.

What Research Gaps and Uncertainties Remain

The research landscape highlights what is still uncertain about the evidence base for Nadix. Key limitations noted are that the follow-up durations were limited across most primary efficacy trials, meaning that long-term effects are not fully established by the existing published data. Comparative evidence is lacking against certain newer topical treatments, particularly in the acne indication. Furthermore, laboratory findings on bacterial activity, such as the Minimum Inhibitory Concentration ( MIC), are primarily microbiological and research does not determine whether an individual will respond similarly; laboratory activity must be contextualized with clinical patient outcomes.

Key Studies & References

  1. Safety and efficacy of nadifloxacin versus clindamycin observed in a tertiary care teaching hospital of Deccan Plateau

Frequently Asked Questions (FAQ)

Common questions about Nadix (FAQ)


Q: How quickly should I expect Nadix to start working?

Studies and official product information indicate that while initial changes in skin lesions may begin during the first few weeks, the full assessment of effectiveness in clinical studies was typically done after 8 to 12 weeks of treatment.


Q: What are the most common side effects of using Nadix?

According to official product labeling, the most frequently reported reactions are limited to the site of application. These common side effects include sensations like itching, a burning feeling, general redness (erythema), and dry skin in the treated area.


Q: Does Nadix interact with common pain relievers like ibuprofen?

Official regulatory documents indicate that because Nadix is a topical medicine with very minimal absorption into the bloodstream, it is considered very unlikely to cause clinically significant interactions with medicines taken orally, such as common pain relievers.


Q: Is it normal to feel a mild burning sensation when first applying Nadix?

Yes, a burning sensation at the application site is listed as a common side effect in the official product information for Nadix. This is a local reaction often experienced during use of the medicine.


Q: What happens if I accidentally miss an application of Nadix?

Regulatory guidelines state that if an application is missed, it should be skipped. The next scheduled dose should be applied at the usual time, and a double quantity must not be used to compensate, according to official administration guidelines.


Q: Can I use Nadix on my face or sensitive areas?

The official product labeling states that Nadix is strictly for application to the skin (dermal use) and must not come into contact with the eyes or other mucous membranes. While use on the face for conditions like acne is a recognized indication, care should be taken to avoid contact with sensitive areas.


Q: What are the signs that Nadix is not working for my infection?

Clinical studies define successful treatment as the clearance or significant improvement of the infection signs. If symptoms appear to worsen or do not begin to improve, consultation with a healthcare professional is generally recommended.


Q: Can I apply makeup or moisturizer over Nadix?

Official warnings advise against applying Nadix simultaneously with other topical preparations, as this may lead to chemical or physical interference at the application site. Due to the warning against simultaneous application of topical preparations, the use of cosmetics like makeup or moisturizers immediately over the treated area may be restricted.


Q: Can I use other topical medications at the same time as Nadix?

Regulatory information advises against co-administration with other topical products, especially those containing irritant substances, such as alcohols or peeling agents. This is to minimize the potential for increased local skin irritation.


Q: Can Nadix be used for conditions other than skin infections?

The official regulatory indications for Nadix specify that it is for the topical treatment of acne vulgaris and certain superficial bacterial skin infections, such as folliculitis and impetigo. Its use is limited to these specific conditions based on official labeling.


Q: Are there any specific foods or drinks I should avoid while using Nadix?

Due to the minimal amount of medicine absorbed into the body when applied to the skin, official product information does not generally require specific dietary restrictions while using topical Nadix.


Q: Can Nadix cause skin discoloration or permanent marks?

Skin hypopigmentation, which is the lightening of the skin color, is documented in the official labeling as a rare side effect. The regulatory information does not specifically address whether any marks or discoloration are permanent.


Q: Can I still go swimming or shower normally while using Nadix?

Official regulatory instructions emphasize that the affected skin area must be properly cleaned and dried before each application. The lack of specific restrictions suggests normal activities can continue, provided that the skin is properly cleaned and dried before the next scheduled application.


Q: Do many users report headaches or dizziness while using Nadix?

Headaches or dizziness are not listed among the common or rare adverse reactions in the official product labeling for the topical formulation. This suggests that these systemic effects are not frequently reported by users.


Q: What should I do if the side effects of Nadix seem too severe?

If severe adverse reactions occur, especially signs of a hypersensitivity or allergic reaction, official guidance suggests seeking medical attention. The product is formally contraindicated if there is a known allergy to any of its components.


Q: What are some unexpected or rare side effects of Nadix?

The most notable rare side effect documented in regulatory labeling is skin hypopigmentation, which involves a lightening of the skin color in the application area. Most effects are local and classified as common.


Q: Is Nadix safe for people with known kidney or liver issues?

Because the medicine is applied topically and only a very small amount enters the bloodstream, regulatory labeling generally indicates that dose adjustment for patients with known kidney or liver impairment is not typically required for this topical formulation.


Q: Does alcohol consumption affect the use of topical Nadix?

Since the medicine is administered topically and has low systemic absorption, official regulatory sources do not typically require a specific warning regarding alcohol consumption.


Q: Are there any common supplements that interact with Nadix?

Due to the very low concentration of the medicine in the bloodstream after topical application, official labeling suggests that clinically significant interactions with orally administered supplements are considered very unlikely.


Q: Is Nadix safe to use if I have other chronic skin conditions?

Official warnings state that the medicine must not be applied to broken or severely damaged skin. If you have chronic skin conditions, consultation with a healthcare professional is advised to determine the appropriateness of Nadix use.


Q: Is it normal for the treated area to peel slightly after using Nadix?

Commonly reported side effects of Nadix include dry skin and contact dermatitis. These local reactions may sometimes lead to slight flaking or peeling of the skin in the area of application.


Q: What happens if I apply too much Nadix at once?

Regulatory information indicates that an acute overdose from applying too much Nadix topically is not expected to cause systemic symptoms due to the low absorption. However, over-application may increase the risk of experiencing local skin irritation.

How should Nadix be stored and disposed of?

How to Store and Dispose of Nadix

Nadix (Nadifloxacin cream) must be stored strictly according to the conditions defined in the regulatory labeling to maintain its stability.

Storage Requirement Official Regulatory Condition
Temperature Store at room temperature, not exceeding 30°C (86°F). Do not freeze
Protection Keep container tightly closed. Protect from excessive heat, moisture, and light
Child Safety Keep out of the sight and reach of children
Stability Discard product after the official expiry date

For disposal, any unused or expired Nadix must be handled according to local/national regulations for medicinal waste. Regulatory guidance advises utilizing a formal drug take-back program or disposing of the product in household trash only after mixing it with an undesirable substance, and it should not be disposed of via wastewater (flushing down toilets or sinks).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nadix found in:

A-Z Index: